23.05.2024 – 12:50
German José Carreras Leukemia Foundation in V
Munich (stones)
“Thanks to nice analysis efforts, leukemia in youngsters is now often simply curable. However, for adults, sadly, the probabilities of survival are nonetheless low. Therefore, the José Carreras Leukemia Foundation will increase its analysis funding to have the ability to give these sufferers a second life,” defined Prof. . Hans-Jochem Kolb in preparation for World Blood Cancer Day (May twenty eighth). Prof. Kolb is a member of the Scientific Advisory Board of the José Carreras Leukemia Foundation and is likely one of the key pioneers of stem cell transplantation and mobile immune remedy in Germany. Currently, solely 30 to 40 out of 100 sufferers with acute myeloid leukemia might be cured completely. Research supported by the José Carreras Leukemia Foundation additionally takes a totally new strategy: sufferers in danger must be handled earlier than their leukemia breaks out.
In 1975, Prof. Kolb had a profitable debut Stem cell transplantation which was completed in Germany and thus saved a younger affected person. The frequent problem was and is that the donor’s bone marrow incorporates not solely necessary blood-forming stem cells, but in addition so-called T cells, which take into account the recipient’s physique as international and assault its organs and tissues. Based on this, Prof. Kolb develops adoptive immunotherapy, which implies that early therapy with chemotherapy or radiation requires a really low dose and subsequently places the affected person at a minimal.
For preliminary contributions José Carreras Gala, which was first broadcast dwell on tv in December 1995, Prof. Kolb based Germany’s mannequin bone marrow transplant middle on the University Hospital of Munich-Großhadern, which opened on June 1, 1997. More than 7,000 stem cell transplants are actually carried out in German clinics yearly. However, issues can nonetheless come up. For each second affected person after an allogeneic hematopoietic stem cell transplant, “Graft-versus-Host-Disease” (Donor versus host response or GvHD). This immune response can harm sure tissues of the affected person, such because the pores and skin, intestines, liver or lungs. In 15 to twenty % of circumstances, even a life-threatening response happens. The José For a few years, the Carrera’s The Leukemia Foundation has been supporting a serious analysis undertaking on the Regensburg University Hospital, amongst others, in order that this drawback might be higher managed.
In addition to stem cell transplants and immunotherapy, different areas of focus CAR T-cell remedy. In the laboratory, extremely efficient, specialised immune cells with genetically modified receptors are then used within the physique to acknowledge and particularly kill leukemia and tumor cells. These receptors are referred to as CARs, “chimeric antigen receptors”.
I a brand new analysis technique it goals to determine and deal with sure high-risk sufferers earlier than they develop leukemia. Prof. Kolb: “Children can have a genetic drawback that will trigger them to develop leukemia sooner or later. In older individuals, this genetic danger could improve over time. The purpose is to type these sufferers in order that they’ll begin therapy early and exactly in order that the life-threatening illness doesn’t come up within the first place. We are nonetheless within the early phases of analysis, however this may very well be one other key to successfully combat leukemia analysis initiatives on this space.”
Dr. Ulrike Serini, Managing Director of the José Carreras Leukemia Foundation: “This yr we are going to as soon as once more dwell as much as our motto ‘Every euro helps save lives and scale back struggling’ and, along with infrastructure and social initiatives, we are going to help the analysis space. 18 alone Research initiatives for a complete of greater than 5 million euros. All analysis initiatives are reviewed extensively by the Scientific Advisory Board, which incorporates main leukemia researchers, and authorized by a common assembly, which convened in Frankfurt underneath the management of José Carreras.
For ongoing funding of analysis initiatives José Carreras Leukemia Foundation In 2019, it was named “Science Foundation of the Year” by the German University Foundation and the Stifterverband. The cause stated that “the inspiration is a beneficiant and beneficiant supporter of leukemia analysis. Its dedication is sensible and exemplary: it makes an necessary contribution to the truth that new strategies are taken in analysis and therapy.”
German José Carreras Leukemia Foundation
The José Carreras Leukemia Foundation helps scientific analysis, infrastructure and social initiatives. In 1987, founder José Carreras turned unwell with leukemia. In gratitude for his restoration, he based the non-profit German José Carreras Leukemia Foundation in 1995 and established a associated basis. Since then, 245 million euros in donations have been collected and nearly 1,500 initiatives have been funded, together with the creation of analysis and therapy facilities, analysis and therapy of leukemia and different hemato-oncological illnesses, the promotion of younger scientists throughout the framework of scholarship applications and the target supporting the work of self-help teams and parenting applications. In 2019, the José Carreras Leukemia Foundation was named Scientific Foundation of the Year by the German University Foundation and the Stifterverband. The German José Carreras Leukemia Foundation eV holds the DZI donation seal, a mark of high quality within the German donation system.
Additional Information: www.carreras-stiftung.de
Press the contact:
German José Carreras Leukemia Foundation
Media and public relations
Elisabethstrasse 23 | 80796 Munich
Phone: 089 / 27 29 04 -40
Email: [email protected]
Original content material from: German José Carreras Leukemia Foundation eV, broadcast information aktuell